Skip to main content
NCD 110.15 · version 1

NCD 110.15: Ultrafiltration, Hemoperfusion and Hemofiltration

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 110.15

Benefit category
Inpatient Hospital Services, Institutional Dialysis Services and Supplies, Outpatient Hospital Services Incident to a Physician's Service
Effective date
08/20/1987
Transmittal
Transmittal 18
Versions published
1
Manual section
110
Hematology/Immunology/Oncology, NCD Manual (Pub. 100-03) chapter 1 part 2

TL;DR

NCD 110.15 sets Medicare's national policy for ultrafiltration, hemoperfusion and hemofiltration under the benefit category "Inpatient Hospital Services, Institutional Dialysis Services and Supplies, Outpatient Hospital Services Incident to a Physician's Service", effective 08/20/1987. This is a process which removes substances from the blood using a charcoal or resin artificial kidney. When used in the treatment of life threatening drug overdose, hemoperfusion is a covered service for patients with or without renal failure. Hemoperfusion… It has been revised once since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

A. Ultrafiltration

This is a process for removing excess fluid from the blood through the dialysis membrane by means of pressure. It is not a substitute for dialysis. Ultrafiltration is utilized in cases where excess fluid cannot be removed easily during the regular course of hemodialysis. When it is performed, it is commonly done during the first hour or two of each hemodialysis on patients who, e.g., have refractory edema. Ultrafiltration is a covered procedure under the Medicare program (effective for services performed on and after September 1, 1979).

Predialysis Ultrafiltration

While the predialysis ultrafiltration procedure requires additional staff care, the facility dialysis rate is intended to cover the full range of complicated and uncomplicated nonacute dialysis treatments. Therefore, no additional facility charge is recognized for predialysis ultrafiltration. The physician's role in ultrafiltration varies with the stability of the patient's condition. In unstable patients, the physician may need to be present at the initiation of dialysis, and available either in- house or in close proximity to monitor the patient carefully. In patients who are relatively stable, but who seem to accumulate excessive weight gain, the procedure requires only a modest increase in physician involvement over routine outpatient hemodialysis.

Occasionally, medical complications may occur which require that ultrafiltration be performed separate from the dialysis treatment, and in these cases an additional charge can be recognized. However, the claim must be documented as to why the ultrafiltration could not have been performed at the same time as the dialysis.

Indications and limitations of coverage

B. Hemoperfusion

This is a process which removes substances from the blood using a charcoal or resin artificial kidney. When used in the treatment of life threatening drug overdose, hemoperfusion is a covered service for patients with or without renal failure. Hemoperfusion generally requires a physician to be present to initiate treatment and to be present in the hospital or an adjacent medical office during the entire procedure, as changes may be sudden. Special staff training and equipment are required.

Develop charges for hemoperfusion in the same manner as for any new or unusual service. One or two treatments are usually all that is necessary to remove the toxic compound; document additional treatments. Hemoperfusion may be performed concurrently with dialysis, and in those cases payment for the hemoperfusion reflects only the additional care rendered over and above the care given with dialysis.

The effects of using hemoperfusion to improve the results of chronic hemodialysis are not known. Therefore, hemoperfusion is not a covered service when used to improve the results of hemodialysis. In addition, it has not been demonstrated that the use of hemoperfusion in conjunction with deferoxamine (DFO), in treating symptomatic patients with iron overload, is efficacious. There is also a paucity of data regarding its efficacy in treating asymptomatic patients with iron overload. Therefore, hemoperfusion used in conjunction with DFO in treating patients with iron overload is not a covered service; i.e., it is not considered reasonable and necessary within the meaning of §1862(a)(1) of the Act.

However, the use of hemoperfusion in conjunction with DFO for the treatment of patients with aluminum toxicity has been demonstrated to be clinically efficacious and is therefore regarded as a covered service.

C. Hemofiltration

This is a process which removes fluid, electrolytes and other low molecular weight toxic substances from the blood by filtration through hollow artificial membranes and may be routinely performed in 3 weekly sessions. Hemofiltration (which is also known as diafiltration) is a covered procedure under Medicare and is a safe and effective technique for the treatment of ESRD patients and an alternative to peritoneal dialysis and hemodialysis. In contrast to both hemodialysis and peritoneal dialysis treatments, which eliminate dissolved substances via diffusion across semipermeable membranes, hemofiltration mimics the filtration process of the normal kidney. The technique requires an arteriovenous access. Hemofiltration may be performed either in facility or at home.

The procedure is most advantageous when applied to high-risk unstable patients, such as older patients with cardiovascular diseases or diabetes, because there are fewer side effects such as hypotension, hypertension or volume overload.

Text reproduced from the CMS Medicare Coverage Database record for NCD 110.15 version 1. View the original on cms.gov.

Local policies that build on this NCD

6 active Local Coverage Determinations cite NCD 110.15 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • Frequency of Hemodialysis, LCD L37537 · Wisconsin Physicians Service Insurance Corporation
  • L34575 Frequency of Hemodialysis · Palmetto GBA
  • L35014 Frequency of Hemodialysis · Novitas Solutions, Inc.
  • L37475 Frequency of Hemodialysis · Wellpoint Federal
  • L37502 Frequency of Hemodialysis · Noridian Healthcare Solutions, LLC
  • L37564 Frequency of Hemodialysis · First Coast Service Options, Inc.

How MACs bill NCD 110.15

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 3 current articles in the Medicare Coverage Database name NCD 110.15, 3 of them with a covered ICD-10-CM list, from 3 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

Contractors with articles that implement NCD 110.15
ContractorArticles
First Coast Service Options, Inc.A56666
Noridian Healthcare Solutions, LLCA55675
Wellpoint FederalA55672

A55672: Billing and Coding: Frequency of Hemodialysis

Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

56 covered ICD-10-CM codes; 1 procedure code: 90999. Local policy: L37475 Frequency of Hemodialysis. Check a diagnosis for 90999.

First covered codes: E83.30 Disorder of phosphorus metabolism, unspecified; E83.39 Other disorders of phosphorus metabolism; E87.20 Acidosis, unspecified; E87.21 Acute metabolic acidosis; E87.22 Chronic metabolic acidosis; E87.29 Other acidosis; …

A55675: Billing and Coding: Frequency of Hemodialysis

Billing and Coding, effective 2025-10-16 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

56 covered ICD-10-CM codes; 1 procedure code: 90999. Local policy: L37502 Frequency of Hemodialysis. Check a diagnosis for 90999.

First covered codes: E83.30 Disorder of phosphorus metabolism, unspecified; E83.39 Other disorders of phosphorus metabolism; E87.20 Acidosis, unspecified; E87.21 Acute metabolic acidosis; E87.22 Chronic metabolic acidosis; E87.29 Other acidosis; …

A56666: Billing and Coding: Frequency of Hemodialysis

Billing and Coding, effective 2023-01-01 · First Coast Service Options, Inc. (09101, 09102, 09201, 09202, 09302) · CMS record

55 covered ICD-10-CM codes; 1 procedure code: 90999. Local policy: L37564 Frequency of Hemodialysis. Check a diagnosis for 90999.

First covered codes: E83.30 Disorder of phosphorus metabolism, unspecified; E83.39 Other disorders of phosphorus metabolism; E87.21 Acute metabolic acidosis; E87.22 Chronic metabolic acidosis; E87.29 Other acidosis; E87.5 Hyperkalemia; …

Revision history

08/1987 - Revised to indicate that hemoperfusion is not covered when used in conjunction with deferoxamine (DFO) to remove iron overload and is covered when used in conjunction with DFO to treat aluminum toxicity. Also revised to cover hemofiltration for renal patients. Effective date 08/20/1987. (TN 18)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 110.15

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 110.15

What does NCD 110.15 cover?

This is a process which removes substances from the blood using a charcoal or resin artificial kidney. When used in the treatment of life threatening drug overdose, hemoperfusion is a covered service for patients with or without renal failure. Hemoperfusion generally requires a physician to be present to initiate treatment and to be present in the hospital or an adjacent medical office during the entire procedure… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 110.15 take effect?

The current version (1) is effective 08/20/1987, published in transmittal 18. This is the only published version.

Does a Local Coverage Determination override NCD 110.15?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.